ERBB2 and neoplasm: Recent studies have shown that HER2 itself regulates the recruitment of tumour-infiltrating immune cells by inducing the expression of chemokine ligand 2 (CCL2) and PD-1 ligands, thereby enhancing the efficacy of immunotherapy (37).